As two of the world's largest and most prolific drugmakers, (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with billions of dollars devoted to research and development, it's almost certain to lead to the discovery of new golden-goose medicines that should enrich shareholders.

But for investors, the details about how those billions will be spent, and how those winning therapies will be found, are critical. And on that basis, it appears that investors will have more to like about AstraZeneca's plans than Pfizer's. Let's investigate why that's the case.

Pfizer's strategic plan for 2030 is to grow total revenue by at least $45 billion, using a combination of internal research and development (R&D) and business development activities like acquisitions, licensing deals, collaborations, and purchasing of attractive pharmaceutical assets.

Continue reading

Source Fool.com